Universitätsklinikum Hamburg-Eppendorf (UKE)

Hamburg 20246

3 studies enrolling now · 14 studies all time

What they study most

AL Amyloidosis, Acute Kidney Injury Due to Sepsis, Acute Myelogenous Leukemia, Acute Myocardial Infarction, Arterial Calcification, Atrial Fibrillation, Autosomal Recessive Hypophosphatemic Rickets Type 2, Children, Chronic Kidney Disease, Combined Hepatocellular and Cholangiocarcinoma, Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency, Gastro-enteropancreatic Neuroendocrine Tumor

Studies at this site

• A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria — Recruiting now
• A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria — Recruiting now
• The Fourth Left Atrial Appendage Occlusion Study — Recruiting now
• Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study — Recruiting now
• ADAPT Study: Long-term Safety Study of INZ-701 in Patients With ENPP1 Deficiency and ABCC6 Deficiency — Recruiting now
• A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET — Running, not enrolling
• Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) — Paused
• Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40% — Completed
• (Revival) Study to Investigate the Efficacy and Safety of Alkaline Phosphatase in Patients With Sepsis-Associated AKI — Stopped early
• Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma — Completed
• Study to Gather Information About the Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following an Acute Heart Attack — Completed
• Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH) — Stopped early
• BAY1436032 in Patients With Mutant IDH1(mIDH1) Advanced Acute Myeloid Leukemia (AML) — Completed
• Study in Subjects With Light Chain (AL) Amyloidosis — Stopped early